Back to the main directory
EarningsReview / Equity
- Hexagon (Buy, TP: SEK130.00) - Waiting for focus to shift to 2025 by DnB Markets
- Unlocking the canine oncology opportunity by BNP Paribas Exane
- Fielmann (FIE GR) by HSBC
- A new era to bring back the Red Devils of old by BNP Paribas Exane
- The best defence is a good offence by BNP Paribas Exane
- Changing for the better by BNP Paribas Exane
- The Analyser - 2024 Edition by BNP Paribas Exane
- Roche Bobois - Matérialisation de nos inquiétudes by MidCap Partners
- Roche Bobois - Materialization of our concerns by MidCap Partners
- MINING NOTE, AAL, BOL, NICKEL, COPPER, STEEL EU by BNP Paribas Exane
- Attacq - FY24 distributable income outperforms by Edison Investment Research
- 春秋航空（601021 CH） by HSBC
- WH Smith (SMWH LN) by HSBC
- Feng Tay Enterprises (9910 TT) by HSBC
- Puuilo - Double-digit sales growth continues by Danske Bank Equity Research
- ChemoMetec A/S - Guidance looks conservative by Danske Bank Equity Research
- Breaking ground on growth by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Running Circles Around Run Specialty by BNP Paribas Exane
- Back to School 2024: Yearning for Earnings by BNP Paribas Exane
- Rusta (Buy, TP: SEK88.00) - Better than feared Q1 results by DnB Markets
- Rusta (Buy, TP: SEK88.00) - Store expansion could top target by DnB Markets
- ChemoMetec (Buy, TP: DKK505.00) - New management, new direction by DnB Markets
- GE to sell down its GEHC stake via debt-for-equity exchange by BNP Paribas Exane
- South African Pharma by HSBC